Clinical trial
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
NCT02435108 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
- Lead sponsor
- Samsung Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 15, 2014
- Completion date
- July 15, 2016
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
c-met positive gastric cancer